Alethea Capital Management’s AbbVie ABBV Stock Holding History

Alethea Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,843	Closed	-$488K	–	31
2024 Q2	$488K	Buy	+2,843	New	+$471K	0.37%	13
2023 Q4	–	Sell	-3,470	Closed	-$517K	–	36
2023 Q3	$517K	Buy	+3,470	New	+$509K	0.64%	7
2023 Q2	–	Sell	-3,990	Closed	-$636K	–	53
2023 Q1	$636K	Buy	+3,990	New	+$610K	0.67%	16
2021 Q4	–	Sell	-8,270	Closed	-$892K	–	87
2021 Q3	$892K	Buy	8,270 +2,101	+34%	+$240K	0.79%	11
2021 Q2	$695K	Buy	+6,169	New	+$695K	0.44%	26
2021 Q1	–	Sell	-12,338	Closed	-$1.32M	–	78
2020 Q4	$1.32M	Buy	+12,338	New	+$1.19M	0.66%	16
2020 Q3	–	Sell	-9,311	Closed	-$914K	–	66
2020 Q2	$914K	Sell	9,311 -429	-4%	-$37.8K	0.53%	15
2020 Q1	$742K	Buy	+9,740	New	+$830K	0.48%	19
2019 Q3	–	Sell	-4,707	Closed	-$342K	–	83
2019 Q2	$342K	Buy	+4,707	New	+$370K	0.22%	67
2018 Q3	–	Sell	-5,085	Closed	-$471K	–	74
2018 Q2	$471K	Sell	5,085 -6,914	-58%	-$675K	0.8%	39
2018 Q1	$1.14M	Buy	11,999 +3,999	+50%	+$439K	1.54%	16
2017 Q4	$774K	Hold	8,000	–	–	1.23%	23
2017 Q3	$711K	Hold	8,000	–	–	0.83%	34
2017 Q2	$580K	Buy	+8,000	New	+$538K	0.66%	46
2016 Q1	–	Sell	-42,583	Closed	-$2.52M	–	60
2015 Q4	$2.52M	Buy	+42,583	New	+$2.45M	2.92%	5

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Alethea Capital Management's ABBV Position: Q3 2024 in Review

Alethea Capital Management sold out of AbbVie (ABBV) in Q3 2024, closing a stake of 2,843 shares — an estimated $488K sold.

Alethea Capital Management first reported a position in ABBV in Q4 2015 and held it in 15 quarters. The position peaked at $2.52M in Q4 2015. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.

Alethea Capital Management reported no remaining AbbVie position as of Q3 2024 after selling out during the quarter.
Alethea Capital Management sold 2,843 AbbVie shares in Q3 2024, an estimated $488K.
Alethea Capital Management first reported a position in AbbVie in Q4 2015 and held it in 15 quarters.
Alethea Capital Management's AbbVie position peaked at $2.52M in Q4 2015.
3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.

Based on Alethea Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.